Shares of Eli Lilly and Company retreated during Monday's trading session, closing down 2.3% at $1,028.07. The pharmaceutical giant's stock experienced volatility, reaching an intraday high of $1,056.84 before falling to a low of $1,023.50. With the decline, Lilly's market capitalization stands near $686 billion.
The downward move occurred against a backdrop of sector-wide weakness. The Health Care Select Sector SPDR Fund, an exchange-traded fund tracking major U.S. healthcare companies, fell approximately 0.9%. This sector underperformance was notable as the SPDR S&P 500 ETF Trust edged higher. Shares of rival Novo Nordisk showed little change in U.S. trading.
Investor sentiment toward Lilly remains heavily tied to the company's portfolio of weight-loss and diabetes medications. The stock's premium valuation, built on growth expectations for these treatments, leaves it sensitive to shifts in demand forecasts, supply chain updates, or pricing dynamics. Even minor developments can trigger significant price movements.
Oncology Milestone in China
Separately, Innovent Biologics announced that Chinese regulators have approved Jaypirca, known generically as pirtobrutinib, for a new indication. The drug is now cleared to treat adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior therapy involving a BTK inhibitor. This class of drugs targets a protein critical for B-cell function.
The approval was based on late-stage trial data demonstrating that Jaypirca delayed disease progression for a median of 14.0 months, compared to 8.7 months for previous standard treatment regimens. Lilly executive Li Wang described the regulatory decision as an "important milestone" for patients who require alternatives after initial BTK inhibitor therapies.
While the approval strengthens Lilly's oncology portfolio, it does not address the central narrative driving the stock. The primary focus for investors continues to be the company's GLP-1 agonist drugs, which mimic a gut hormone to suppress appetite and lower blood sugar. Key concerns include the pace of market access expansion and Lilly's ability to maintain net pricing for these therapies.
Building Inventory for Oral GLP-1 Launch
In preparation for a potential U.S. launch, Eli Lilly disclosed on February 12 that it has accumulated $1.5 billion worth of pre-launch inventory for its experimental oral GLP-1 pill, orforglipron. This stockpile represents a substantial increase from roughly $550 million a year ago, signaling the company's operational readiness to swiftly commercialize the drug upon regulatory clearance. The U.S. Food and Drug Administration is expected to complete its review in April.
However, clinical data released on February 26 presented a mixed picture. While orforglipron demonstrated superior blood sugar control and weight loss compared to Novo Nordisk's oral semaglutide in a head-to-head study, the Lilly therapy was associated with higher rates of gastrointestinal side effects. Notably, treatment discontinuation increased at the highest dose, raising some concerns among analysts.
Market participants are also anticipating commentary from Lilly's management. Chief Financial Officer Lucas Montarce is scheduled to speak at the TD Cowen Annual Health Care Conference at 3:10 p.m. Eastern Time.
The next major scheduled event for investors is the company's first-quarter earnings conference call, set for April 30. In the interim, attention will remain fixed on any updates regarding the supply of obesity drugs, clarity on pricing strategies, and the timeline for the FDA's final decision on orforglipron.
